共 230 条
[21]
Roden M(2010)One-year effectiveness and safety of open-label losartan/hydrochlorothiazide combination therapy in Japanese patients with hypertension uncontrolled with ARBs or ACE inhibitors Hypertens Res 33 320-885
[22]
Merker L(2016)Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study Lancet Diabetes Endocrinol 4 211-390
[23]
Christiansen AV(2015)Does antihypertensive treatment with renin-angiotensin system inhibitors prevent the development of diabetic kidney disease? BMC Pharmacol Toxicol 16 22-322
[24]
Roux F(2014)An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention Hypertension 63 878-1122
[25]
Salsali A(2014)The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2014) Hypertens Res 37 253-1114
[26]
Kim G(2016)Liraglutide and cardiovascular outcomes in type 2 diabetes N Engl J Med 375 311-undefined
[27]
Stella P(2016)Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME Study? A unifying hypothesis Diabetes Care 39 1115-undefined
[28]
Woerle HJ(2016)CV protection in the EMPA-REG OUTCOME Trial: a “thrifty substrate” hypothesis Diabetes Care 39 1108-undefined
[29]
Broedl UC(undefined)undefined undefined undefined undefined-undefined
[30]
Matthaei S(undefined)undefined undefined undefined undefined-undefined